Gilead Sciences announced that the FDA has accepted for review its New Drug Application (NDA) for idelalisib, a targeted oral inhibitor of PI3K delta, for the treatment of indolent non-Hodgkin lymphoma (iNHL).

Related: Hematologic Cancers Resource Center

The NDA submission was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.


Continue Reading

Idelalisib is an investigational, highly selective, oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, which is hyperactive in many B-cell malignancies. Inhibition of this kinase blocks the activation, proliferation, survival, and trafficking of B lymphocytes.

Previously the FDA had granted idelalisib a Breakthrough Therapy designation for relapsed chronic lymphocytic leukemia (CLL).

For more information call (800) 445-3235 or visit Gilead.com.

This article originally appeared on MPR